Aurinia Pharmaceuticals (AUPH)
(Delayed Data from NSDQ)
$11.37 USD
-0.06 (-0.52%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $11.36 -0.01 (-0.09%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum A VGM
Fundamental Charts
About Market Cap
As of the previous market close, Aurinia Pharmaceuticals Inc has a market cap of $1.50B, which represents its share price of $11.43 multiplied by its outstanding shares number of 131.63M. As a small-cap company, AUPH's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
AUPH 11.37 -0.06(-0.52%)
Will AUPH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AUPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AUPH
Aurinia (AUPH) Upgraded to Buy: Here's What You Should Know
Aurinia Pharmaceuticals (AUPH) Q2 Earnings Miss Estimates
AUPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options
Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains?
Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?
Other News for AUPH
Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade)
Aurinia Pharmaceuticals Reaches Analyst Target Price
Insider Sell: Greg Keenan Sells 20,000 Shares of Aurinia Pharmaceuticals Inc (AUPH)
Aurinia Pharmaceuticals: Strong Financial Performance and Promising Future Justify Buy Rating
AUPH Analyst Rating Update: RBC Capital Raises Price Target | AUPH Stock News